{"contentid": 488384, "importid": NaN, "name": "On vaccine side effects, big pharma's not all in it together", "introduction": "Johnson & Johnson reportedly reached out to fellow vaccine developers to work together on evaluating possible vaccine-linked blood clotting events, but was rebuffed.", "content": "<p><span style=\"font-weight: 400;\">Johnson &amp; Johnson (NYSE: JNJ) </span><a href=\"https://www.wsj.com/articles/j-j-privately-asked-rival-covid-19-vaccine-makers-to-probe-clotting-risks-11618570802\"><span style=\"font-weight: 400;\">reportedly</span></a><span style=\"font-weight: 400;\"> reached out to fellow vaccine developers to work together on evaluating possible vaccine-linked blood clotting events, but was rebuffed.</span></p>\n<p><span style=\"font-weight: 400;\">Following reports that a rare form of blood clot, cerebral venous sinus thrombosis (CVST), might be linked to its coronavirus vaccine, J&amp;J privately contacted AstraZeneca (LSE: AZN), Pfizer (NYSE: PFE) and Moderna (Nasdaq: MRNA) to study the events, and in order to coordinate a public response.</span></p>\n<p><span style=\"font-weight: 400;\">In the USA, use of J&amp;J&rsquo;s vaccine has been suspended while public health authorities investigate a possible connection with a handful of CVST cases.</span></p>\n<p><span style=\"font-weight: 400;\">Several European countries have altered their vaccination schedules after AstraZeneca&rsquo;s jab, Vaxzevria, was tentatively linked with cases of CVST.&nbsp;</span></p>\n<p><span style=\"font-weight: 400;\">According to people familiar with the matter, the Wall Street Journal reported, executives at Pfizer and at Moderna considered that their options were unaffected by the blood clots, and did not see any need to replicate investigations underway at regulatory authorities.</span></p>\n<p><span style=\"font-weight: 400;\">They were also concerned their vaccines could be tarnished by association with the J&amp;J and AstraZeneca jabs.</span></p>\n<h2><strong>Viral vector technologies</strong></h2>\n<p><span style=\"font-weight: 400;\">Unlike the vaccines offered by Moderna and by Pfizer and BioNTech (Nasdaq: BNTX), which are based on novel mRNA platforms, the J&amp;J and AstraZeneca jabs both use a vital vector platform.</span></p>\n<p><span style=\"font-weight: 400;\">This has led some to suggest that there may be a class-wide safety issue, with US FDA scientist Peter Marks stating it was &ldquo;plainly obvious&rdquo; that the cases in the USA looked &ldquo;very similar&rdquo; to those noted in Vaxzevria-inoculated Europeans.</span></p>\n<p><span style=\"font-weight: 400;\">Any suggestion of a class-wide issue has been </span><a href=\"https://www.thepharmaletter.com/article/russia-seeks-to-distance-sputnik-v-from-blood-clotting-cases\"><span style=\"font-weight: 400;\">strenuously denied</span></a><span style=\"font-weight: 400;\"> by the backers of Russia&rsquo;s vaccine, Sputnik V, which uses a similar approach.</span></p>\n<p><span style=\"font-weight: 400;\">The Gamaleya Center, which developed the product, said &ldquo;there is no reason and no justification to extrapolate safety data from one vaccine to safety data from other vaccines.&rdquo;</span></p>\n<p><span style=\"font-weight: 400;\">Scientists at J&amp;J have also sought to distance their option from the AstraZeneca jab, with research published in the New England Journal of Medicine noting that &ldquo;the two adenoviral vector COVID-19 vaccines may have quite different biologic effects.&rdquo;</span></p>", "date": "2021-04-19 11:21:00", "meta_title": NaN, "meta_keywords": "vaccine, Johnson, blood, AstraZeneca, vaccines, events, CVST, Pfizer, Moderna, cases, vector, reportedly, safety, fellow, reached, rebuffed, clotting, work", "meta_description": "Johnson & Johnson reportedly reached out to fellow vaccine developers to work together on evaluating possible vaccine-linked blood clotting events, but was rebu", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 1, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-04-19 11:11:56", "updated": "2021-04-20 10:44:00", "access": NaN, "url": "https://www.thepharmaletter.com/article/on-vaccine-side-effects-big-pharma-s-not-all-in-it-together", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "lab_biotech_research_vaccine_big.jpg", "image2id": "lab_biotech_research_vaccine_small.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Biotechnology", "therapy area_tag": "Vaccines", "topic_tag": "Coronavirus, Focus On, Public health, Regulation", "geography_tag": "UK, USA", "company_tag": "AstraZeneca, Johnson & Johnson, Moderna, Pfizer", "drug_tag": "Ad26.COV2.S, Comirnaty, mRNA-1273, Vaxzevria", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-04-19 11:21:00"}